News from the Front Line COVID-19 Critical Care Alliance (FLCCC) states (website):
NIH (National Institutes of Health) Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19. Ivermectin is Now a Treatment Option for Health Care Providers!
Jan 14, 2021 – One week after Dr. Paul Marik and Dr. Pierre Kory – founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC) – along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their recommendation and now considers Ivermectin an option for use in COVID-19.
Their recommendation has now been upgraded to the same level as those for widely used monoclonal antibodies & convalescent plasma, which is a “neither for nor against” recommendation. The significance of this change is that the NIH has decided to no longer recommend against the use of ivermectin in the treatment of COVID-19 by the nation’s health care providers. A consequence of this change is that ivermectin has now been made a clear therapeutic option for patients.
This paragraph about Ivermetic contained on FLCCC's FAQ page here provides useful background info:
The discovery of Ivermectin in 1975 was awarded the 2015 Nobel Prize in Medicine given its global impact in reducing onchocerciasis (river blindness), lymphatic filiariasis, and scabies in endemic areas of central Africa, Latin America, India and Southeast Asia. It has since been included on the WHO’s “List of Essential Medicines with now over 4 billion doses administered. Numerous studies report low rates of adverse events, with the majority mild, transient, and largely attributed to the body’s inflammatory response to the death of parasites and include itching, rash, swollen lymph nodes, joint paints, fever and headache.
On their website, FLCCC host several really interesting documents on Ivermetin covering its discovery, history, studies and use. Embedded below is one of the documents, which is well worth reading and/or scanning. FLCCC's Ivermetin protocols are detailed towards the end of the document, starting page 24 [The PDF file can be downloaded direct from the FLCCC site here - or can be opened direct in Google PDF reader by clicking here.]
The document linked contains this really interesting ***MUST SEE*** set of graphs on page 18 (click to enlarge). It is titled: 'Decrease in total case incidences and total deaths/population of COVID-19 in the over 60 population among 8 Peruvian states after deploying mass ivermectin distribution campaigns'. The things to note on the graphs is how the red line (which is total deaths per 100,000 people), peaks and then falls dramatically right after ivermectin intervention (which point itself can be seen on the boundary where the graph background changes from grey to white). Also note how in some regions CV19 cases rise substantially again at a time after ivermectin intervention, yet the red line (total deaths per 100k) remains low.
Below is the FLCCC response to the 'NIH Guideline Committee Recommendation on ivermectin use in COVID-19' as to why FLCCC considers ivermectin is worthy of positive recommendation for use with CV19 (rather than a 'neutral' recommendation). [Click here to open direct in Google PDF reader.]